I'm LongbridgeAI, I can summarize articles.

Start

Abbott Laboratories is underpriced as investors view it merely as a slow-growth dividend stock, ignoring its strategic pivot. Key growth drivers include the FreeStyle Libre CGM franchise with significant untapped market potential and the $21B acquisition of Exact Sciences to launch a Cancer Diagnostics unit. Despite recent stock declines, Abbott maintains strong financial performance with consistent earnings beats and dividend increases, suggesting a disconnect between market perception and fundamental value.